2026-09-11

Nitin Prabhakar, Managing Director (MD), Anton Paar India, puts stronger emphasis on how the company enables Indian pharmaceutical manufacturers to produce globally accepted, high-quality products rather than promoting products directly, in an exclusive interaction with Pharma Industrial India.

Q. As India’s pharmaceutical industry transitions from volume-driven manufacturing to innovation-led drug development, how are advanced analytical and characterisation technologies enabling this shift, and what role do they play in enhancing product quality and global competitiveness?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost—it is increasingly competing on quality, innovation and global credibility. Analytical instrumentation has become a strategic enabler of this transformation because innovation can only succeed when it is backed by reliable and reproducible scientific data.

Whether it is developing complex formulations, improving process understanding, or ensuring consistent product quality, advanced analytical technologies help manufacturers make informed decisions throughout the product lifecycle.

At Anton Paar India, our focus is to equip pharmaceutical companies with world-class analytical solutions that help them meet the highest international standards. We believe Indian manufacturers have the capability to become global innovation leaders, and our role is to provide the precision, reliability and scientific confidence needed to produce medicines that are accepted in every regulated market across the world.

Q. With pharmaceutical products becoming increasingly complex—from Active Pharmaceutical Ingredients (APIs) and novel formulations to biologics—what are the most critical analytical and characterisation challenges laboratories face today, and how can advanced testing technologies help address them?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost. The biggest challenge today is the increasing complexity of pharmaceutical products. Active Pharmaceutical Ingredients (APIs) require extremely precise characterisation and impurity analysis. Formulations demand a deeper understanding of material properties that directly influence stability and bioavailability, while biologics introduce entirely new levels of molecular complexity.

At the same time, manufacturers are expected to reduce development timelines while maintaining uncompromising quality and regulatory compliance.

This is where advanced analytical technologies make a real difference. Accurate measurement, reliable data and process understanding allow manufacturers to identify potential issues early, optimise formulations faster and consistently deliver products that meet stringent global quality expectations. Our objective at Anton Paar is to help Indian pharmaceutical companies transform analytical excellence into a competitive advantage.

Q. As regulatory expectations around data integrity, traceability and product quality continue to evolve, how are pharmaceutical laboratories strengthening their analytical infrastructure to ensure compliance while maintaining operational excellence?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost—it is Indian pharmaceutical companies that have significantly strengthened their quality culture over the last few years. We see growing investments in modern laboratories, digital data management, automated analytical workflows and technologies that support regulatory compliance from development through commercial manufacturing. Data integrity is now viewed not simply as a regulatory obligation but as an essential business requirement for maintaining global market access.

Anton Paar supports this journey by providing analytical solutions designed for accuracy, traceability and compliance with international regulatory expectations. Our objective is to help Indian manufacturers generate reliable, audit-ready data that builds confidence with regulators and customers worldwide while improving operational efficiency.

Q. How is laboratory automation reshaping the use of analytical and testing instruments in pharmaceutical R&D and quality control, and what impact is it having on productivity, data quality, and decision-making?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost—it is the automation that is fundamentally changing laboratories by making them more efficient, consistent, and data driven. It reduces manual intervention, minimises variability and enables faster decision-making without compromising analytical quality.

In quality control, automation improves consistency and shortens release timelines. In research and development, it allows scientists to evaluate more samples, optimise formulations
more efficiently and accelerate innovation.

At Anton Paar, we see automation as an important step toward helping Indian pharmaceutical companies compete globally.

By integrating intelligent analytical systems with automated workflows, laboratories can deliver faster, more reliable results while maintaining the high standards expected by international regulators.

Q. With Artificial Intelligence (AI)-powered analytics, connected laboratory instruments and digital workflows becoming integral to modern laboratories, how prepared is the Indian pharmaceutical industry to embrace this next generation of analytical technologies?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost—it is the industry which is making encouraging progress. Large pharmaceutical companies are
already investing in digital laboratories and connected analytical environments, while many mid-sized companies are now accelerating their digital transformation initiatives.

The real opportunity lies in combining analytical data with AI to improve process understanding, predict deviations, optimise maintenance and enhance decision-making. Anton Paar is actively supporting this evolution by developing intelligent analytical solutions that integrate seamlessly into digital laboratory ecosystems. We believe connected instruments, automated data management, and advanced analytics will become essential for pharmaceutical companies seeking to maintain competitiveness in global markets.

Q. In today’s fast-paced pharmaceutical environment, how can advanced analytical testing and process measurement technologies help manufacturers accelerate development and production while ensuring regulatory compliance and consistent product quality?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost—it is speed, compliance, and quality that should reinforce each other rather than compete with one another. The key is building quality into every stage of the manufacturing process through robust analytical science and real-time process understanding.

Companies that invest in advanced analytical technologies, automated quality systems and digital workflows are better positioned to identify process variations early, reduce rework, accelerate product release and consistently meet regulatory expectations.

At Anton Paar, we believe precision measurement is the foundation of quality manufacturing. By providing accurate analytical insights throughout development and production, we help pharmaceutical manufacturers achieve operational efficiency while delivering products that meet the expectations of regulators and patients around the world.

Q. Looking ahead to 2030, what emerging trend in analytical science, laboratory technology, or process measurement do you believe will have the greatest impact on the future of pharmaceutical manufacturing, and why?

Nitin Prabhakar: India is no longer competing only on manufacturing scale or cost. The defining trend will be the transition from traditional quality control to intelligent, data-driven manufacturing supported by advanced analytics, automation and AI.

By 2030, pharmaceutical manufacturing will increasingly rely on continuous monitoring and real-time analytical data to predict, optimise and control production processes. This will reduce variability, improve efficiency, strengthen compliance and accelerate product development.

For Indian pharmaceutical companies, this represents an opportunity to move beyond being one of the world’s largest manufacturers to becoming one of the world’s most trusted producers of high-quality medicines.

Anton Paar is committed to supporting this journey by providing globally trusted analytical solutions that enable Indian manufacturers to produce medicines that consistently meet the highest international standards and strengthen India’s position as a preferred pharmaceutical partner for the world.